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Abstract
Severe hypercalcemia in infants is usually attributed to genetic etiologies and less commonly to acquired ones. An
8-week-old girl presented with failure to thrive, mild respiratory distress, and life-threatening hypercalcemia (23.5
mg/dL). Serum 1,25(OH)2-vitamin D (1,25(OH)2-D) level was elevated and parathyroid hormone undetectable.
Evaluation for genetic mutations and malignant etiologies of hypercalcemia was negative. Treatment with intravenous
hydration, loop diuretic, and calcitonin failed to correct the hypercalcemia, which was subsequently controlled with
bisphosphonate therapy. Due to progressive respiratory deterioration, a bronchopulmonary lavage was done on
day 17 of her hospitalization disclosing Pneumocystis jiroveci infection. The subsequent immunological investigation
showed no abnormalities. She was treated with trimethoprim/sulfamethoxazole resulting in gradual clearing of her
lungs and normalization of serum 1,25(OH)2-D level. A year later, she remains healthy with normal biochemical
parameters of mineral metabolism. We conclude that in a child with hypercalcemia with suppressed parathyroid
hormone and elevated 1,25(OH)2-D, once the genetic etiology for elevated 1,25(OH)2-D and malignancy are ruled
out, one should investigate closely for a chronic granulomatous disease. Among the latter Pneumocystis jiroveci
pneumonia infection should be considered even in an immunocompetent child.
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Introduction
In immunocompetent children, Pneumocystis infection
is mild and may present as an upper respiratory tract
infection. On the other hand, Pneumocystis is a lifethreatening infection in children who are immunocompromised from conditions such as HIV infection,
chemotherapy, corticosteroid therapy, transplantation,
and primary immunodeficiency states.1,2 Few patients
with Pneumocystis infection develop hypercalcemia
caused by elevated 1,25(OH)2-vitamin D (1,25(OH)2-D).3-5
The latter is due to the fact that in chronic granulomatous
conditions activated macrophages produce 1,25(OH)2-D
dependent on the substrate, 25(OH)-vitamin D (25(OH)D) availability, but is not regulated by feedback from calcium, parathyroid hormone (PTH), or 1,25(OH)2-D.6-9

In this report, we describe a 2-month-old immunocompetent infant who presented with nonspecific symptoms of failure to thrive and lethargy associated with
life-threatening hypercalcemia that preceded by 2 weeks
the development of Pneumocystis jiroveci pneumonia
(PJP). The hypercalcemia was related to increased
ectopic synthesis of 1,25(OH)2-D, which was aggravated by inappropriate vitamin D supplementation. The
1

Children’s Mercy Hospital, University of Missouri at Kansas City,
MO, USA
Corresponding Author:
Judith Sebestyen VanSickle, Division of Pediatric Nephrology,
Children’s Mercy Hospital, 2401 Gillham Road, Kansas City, MO
64108, USA.
Email: jvansickle@cmh.edu

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits noncommercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified
on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

2

Global Pediatric Health

Table 1. Serum Calcium, Ionized Calcium, Parathyroid Hormone (PTH), 25(OH)-Vitamin D, 1,25(OH)2-Vitamin D, and
Urinary Calcium/Creatinine Ratio at Presentation, During Active Therapy, and Follow-up in an Infant With Pneumocystis jiroveci
Pneumoniaa.

Reference range
At admission (day 0)
First dose of bisphosphonate (day 3)
Third dose of bisphosphonate (day 5)
1 Week
2 Weeks
First dose of TMP/SMX (3 weeks)
End of TMP/SMX therapy (24 weeks)
On regular diet (36 weeks)

Serum Calcium
(mg/dL)

iCa
(mmol/L)

PTH
(pg/mL)

25(OH)Vitamin D
(ng/mL)

1,25(OH)2Vitamin D
(pg/mL)

Urine Ca/
Creatinine
(mg/mg)

8.6-10.5
24.3
18.8
17.9
15.8
10.6
9.6
10.0
10.4

1.13-1.37
>3.30
2.60
2.20
2.04
1.36
1.20
1.16
1.20

10-89
<3.4

30-100
165

24-86
237

<0.8
2.2
3.1

<3.4
<3.4
<3.4
41
19

26
46

228
87

3.4
<0.04
<0.04

Abbreviations: iCa, ionized calcium; TMP/SMX, trimethoprim/sulfamethoxazole.
a
Serum creatinine and albumin concentrations were normal for age throughout the whole period.

life-threatening hypercalcemia was corrected by
bisphosphonate therapy, and normalization of serum
1,25(OH)2-D was achieved by treating the granulomatous disease with trimethoprim/sulfamethoxazole (TMP/
SMX).

Case Report
The infant girl was born at full term with a birth weight
of 4300 g via spontaneous vaginal delivery. She presented at 8 weeks of age for evaluation of failure to
thrive, lethargy, and dehydration. The parents reported
that she was taking 30 to 60 mL of expressed breast milk
every 2 hours and vitamin D 400 IU/day, and having ˜20
wet diapers/day. Her admission weight was 3710 g (2nd
percentile), length 58.4 cm (60th percentile), and head
circumference 39.0 cm (75th percentile). In the preceding 3 weeks, she had lost ˜1 kg in weight. Her physical
exam revealed no dysmorphic features, sunken anterior
fontanelle, sunken eyes, anicteric sclera, and no skin
rash. Her lungs sounded clear and she had normal heart
rate and sounds without murmurs. The abdominal exam
was benign without hepatosplenomegaly. Her extremities showed no deformities.
As shown in Table 1, on admission the laboratory
evaluation showed serum calcium 24.3 mg/dL, ionized
calcium (iCa) >3.30 mmol/L, undetectable PTH, creatinine 0.38 mg/dL, albumin 3.4 g/dL, and urine calcium/
creatinine ratio 2.2 mg/mg. A repeat discussion with the
family disclosed that the girl was erroneously receiving
4000 units/day of vitamin D instead of the prescribed
400 units/day. Serum 25(OH)-D was mildly elevated at
165 ng/mL (normal 30-100 ng/mL), and 1,25(OH)2-D
was markedly elevated at 237 pg/mL (24-86 pg/mL).

Additional evaluation for hypercalcemia showed normal
serum PTH-related peptide, vitamin A, 24,25(OH)2vitamin D level, alkaline phosphatase activity, no mutation in CYP24A1 gene, and normal gene microarray. On
admission, the chest X-ray showed only mildly increased
parahilar bronchial markings. Computed tomography of
the chest, abdomen, and pelvis showed no tumors.
Skeletal survey showed no lesions or metabolic bone
disease. The renal ultrasound showed mildly enlarged
echogenic kidneys (right 6.8 cm and left 6.0 cm).
The child received intravenous hydration, loop
diuretic, and calcitonin for the life-threatening hypercalcemia. The vitamin D supplementation was discontinued, and she was placed on breast milk and low calcium
and vitamin D free formula Calcilo XD (Abbott). At the
end of 48 hours serum calcium had only decreased to
18.8 mg/dL. She was subsequently treated with zoledronic acid on 3 successive days (cumulative dose 0.375
mg). In the next 2 weeks serum calcium and iCa gradually decreased and normalized on day 15 (Table 1).
In the 2-week period following admission she experience gradual worsening tachypnea requiring supplemental oxygen, which progressed into respiratory
distress. On hospital day 17, a chest computed tomography revealed a ground-glass appearance with interlobular septal thickening in both upper and lower lobes
(Figure 1). A bronchoscopy with alveolar lavage and
wedge lung biopsy was performed, which were both
positive for PJP. TMP/SMX therapy was initiated on day
21 of her hospitalization. An immunologic workup
(complete blood counts, peripheral smears, serum
immunoglobulin levels, granulocyte oxidative burst test,
T- and B-cell flow cytometry, in vitro T-cell function to
mitogens, specific antigens, and allogenic lymphocytes)
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Figure 1. Chest computed tomography shows diffuse
ground-glass and parabronchiolar septal thickening within the
bilateral lower lobes.

and genetic studies (microarray, T-cell/B-cell clonality
by polymerase chain reaction) were all normal.
At discharge, at 12 weeks of age, her respirations
were normal and the lungs were clear to auscultation.
She was sent home on TMP/SMX, and breast milk supplemented by Calcilo XD formula. She was treated with
TMP/SMX for a total of 21 weeks. At 24 weeks of follow-up (Table 1), 25(OH)-D level had decreased to 26
ng/mL while serum 1,25(OH)2-D level was still high at
228 pg/mL. At 32 weeks Calcilo XD was changed to
whole milk. On her last follow-up (36 weeks), she was
taking regular diet without vitamin D supplementation.
She appeared well and was developing appropriately.
Her length was 80.8 cm (58th percentile), weight 10.3
kg (28th percentile), and head circumference 46.9 cm
(62nd percentile). Serum calcium, iCa, 25(OH)-D and
1,25(OH)2-D, and urine calcium were in the normal
range (Table 1). The skeletal survey was normal. The
follow-up ultrasound showed normal kidneys (right 7.0
cm and left 6.9 cm).

Discussion
Our report highlights severe life-threatening hypercalcemia in an infant during the prodromal phase of PJP from
increased 1,25(OH)2-D synthesis by macrophages,
which was further aggravated by inappropriately high
intake of vitamin D supplementation. Hypercalcemia in
association with Pneumocystis infection was first
reported in an infant in 1965 but was attributed to vitamin D toxicity.10 Recently hypercalcemia in PJP has also
been reported in recipients of kidney transplant receiving immunosuppressive therapy.4,5
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Hypercalcemia occurs when there is an imbalance
between calcium entry and exit from the blood from
changes in gastrointestinal absorption, urinary excretion, and/or bone deposition or resorption. The etiology
of hypercalcemia can be examined as conditions associated with elevated PTH versus those in which PTH is
suppressed, and the latter can be further divided into
conditions in which 25(OH)-D and 1,25(OH)2-D are
normal or elevated.3 Our patient had undetectable PTH,
mildly elevated 25(OH)-D, and markedly elevated
1,25(OH)2-D concentrations. A consideration for hypervitaminosis D was made due to inappropriate intake of
vitamin D supplementation, but generally in cases of
vitamin D toxicity the serum levels of 25(OH)-D are
>250 ng/mL,11 and as shown in humans12 and rats,13
concomitant serum 1,25(OH)2-D concentration is either
normal or only mildly elevated. Thus, hypervitaminosis
D was not responsible for the life-threatening hypercalcemia in our patient.
The prohormones, ergocalciferol, and cholecalciferol
are hydroxylated in the liver into 25(OH)-D by microsomal cytochrome P450 enzymes. This enzyme activity
has no feedback control, and thus the serum 25(OH)-D
level reflects body stores of the vitamin, which depend
on dietary intake and sunlight exposure. The elevated
25(OH)-D in our case report can be explained by the
inappropriately high vitamin D supplementation. The
25(OH)-D circulates bound to vitamin D binding protein
and is delivered to the kidney and other tissues where it
is hydroxylated to 1,25(OH)2-D. Both 25(OH)-D and
1,25(OH)2-D are catabolized by 24-hydroxylase enzyme
into 24,25(OH)2-vitamin D and 1,24,25(OH)3-vitamin
D, respectively.14 In infants with idiopathic infantile
hypercalcemia, mutations in CYP24A1 gene encoding
the 24-hydroxylase enzyme lead to insufficient catabolism of 25(OH)-D and 1,25(OH)2-D, resulting in high
serum levels of these metabolites and low levels of
24,25(OH)2-vitamin D.14 Our case had neither a mutation in CYP24A1 gene nor low 24,25(OH)2-vitamin D
level, thus excluding this entity as an etiology.
High serum levels of 1,25(OH)2-D, and subsequent
hypercalcemia, have been described in granulomatous
condition such as sarcoidosis, tuberculosis, and so on,
resulting from increased activity of 1-alpha-hydroxylase
by activated macrophages.3 In contrast to the kidney,
where production of 1,25(OH)2-D is tightly regulated by
feedback from calcium, PTH, and 1,25(OH)2-D, it is not
regulated in activated macrophages.6-9 The ectopic
1,25(OH)2-D production is substrate dependent, and
hypercalcemia is more likely and severe with higher
25(OH)-D levels.6,7 The elevated 1,25(OH)2-D causes
increased calcium absorption from the gut.15 Since production of 1,25(OH)2-D is substrate dependent in
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activated macrophages, the smoldering PJP infection in
our immunocompetent patient combined with inappropriate vitamin D supplementation, created a “perfect
storm” for life-threatening hypercalcemia. On follow-up
we noticed that despite adequate therapy for PJP, it took
more than 30 weeks for serum 1,25(OH)2-D levels to
normalize, likely indicating slow resolution of macrophage activity. Treatment should start with intravenous
hydration, loop diuretics, and calcitonin, but with
increased experience with bisphosphonates they should
be considered early in the management of hypercalcemia.15,16 We have previously shown that these anti-bone
resorption agents can be safely used in children.16
In summary, in a child with hypercalcemia serum
levels of PTH, 25(OH)-D, and 1,25(OH)2-D are of great
help with the initial diagnostic workup. In a child with
hypercalcemia with suppressed PTH and elevated
1,25(OH)2-D, once the genetic etiology for elevated
1,25(OH)2-D (CYP24A1 gene mutation) is ruled out,
one should investigate closely for a chronic granulomatous disease. Among the latter PJP infection should be
considered even in an immunocompetent child as hypercalcemia may occur during the prodrome, and more
likely if the child is on vitamin D supplementation.
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